Southeast Oral & Maxillofacial Associates.
Division of Oral and Maxillofacial Pathology Laboratory, The University of North Carolina Adams School of Dentistry.
J Pediatr Hematol Oncol. 2023 Jul 1;45(5):278-280. doi: 10.1097/MPH.0000000000002608. Epub 2022 Dec 19.
Central giant cell granuloma of the jaw (CGCJ) can be locally aggressive and result in facial and dental deformity. A child with CGCJ was treated surgically and with denosumab with a response but life-threatening toxicity. Imatinib, a tyrosine kinase inhibitor, was prescribed based on clinical similarities between CGCJ and cherubism, for which Imatinib has been effective. Within 2 months, a computed tomographic scan showed significant ossification, which increased over the following 8 months. This case suggests that tyrosine kinase inhibitors may be an effective option, and one with limited toxicity, for CGCJ.
颌骨中央性 giant cell 肉芽肿（CGCJ）具有局部侵袭性，可导致面部和牙齿畸形。一名患有 CGCJ 的儿童接受了手术和 denosumab 治疗，取得了缓解但出现了危及生命的毒性。根据 CGCJ 和 cherubism 之间的临床相似性，酪氨酸激酶抑制剂伊马替尼被用于治疗 cherubism，并且伊马替尼对 cherubism 有效。在 2 个月内，计算机断层扫描显示明显的骨化，并且在接下来的 8 个月内持续增加。本病例提示，酪氨酸激酶抑制剂可能是 CGCJ 的一种有效选择，且具有有限的毒性。
